Supernus Pharmaceuticals
SUPN
250 hedge funds and large institutions have $1.93B invested in Supernus Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 67 increasing their positions, 98 reducing their positions, and 29 closing their positions.
54% more call options, than puts
Call options by funds: $3.47M | Put options by funds: $2.25M
17% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 29
15% more capital invested
Capital invested by funds: $1.67B → $1.93B (+$255M)
2% more funds holding
Funds holding: 246 → 250 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.33% less ownership
Funds ownership: 105.91% → 103.59% (-2.3%)
32% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 98
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$38.4M |
| 2 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$6.04M |
| 3 |
HSBC Holdings
London,
United Kingdom
|
+$5.27M |
| 4 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$5.17M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$32.1M |
| 2 |
Morgan Stanley
New York
|
-$23.7M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$5.49M |
| 4 |
Two Sigma Investments
New York
|
-$5.1M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$4.32M |
SUPN Hedge Fund Activity: Q1 2024 in Review
250 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2024, worth a combined $1.93B — up 15% from $1.67B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new SUPN positions and 29 closed out — a net gain of 5 holders — while 67 added to existing stakes and 98 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $38.4M. The largest seller was Armistice Capital, cutting an estimated $32.1M.
- 250 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2024, up from 246 in Q4 2023.
- Funds reported $1.93B of Supernus Pharmaceuticals stock for Q1 2024, up 15% quarter-over-quarter.
- 34 funds opened new Supernus Pharmaceuticals positions in Q1 2024 and 29 closed out, a net change of +5 holders.
- The largest Supernus Pharmaceuticals buyer in Q1 2024 was Woodline Partners, an estimated $38.4M added.
- The largest Supernus Pharmaceuticals seller in Q1 2024 was Armistice Capital, an estimated $32.1M sold.
Based on aggregated 13F filings for Q1 2024.